Catalyst Pharmaceutical Partners, Inc. Sample Contracts

Catalyst Pharmaceuticals, Inc. – CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED SUCH INFORMATION HAS BEEN MARKED HEREIN WITH [***] AMENDMENT NO. 2 TO LICENSE AGREEMENT (May 30th, 2019)

This AMENDMENT NO. 2 TO LICENSE AGREEMENT (herein referred to as “Amendment No. 2”) is made and entered effective as of the 29th day of May, 2019 (the “Amendment Effective Date”), by and between BioMarin Pharmaceutical Inc., a Delaware corporation (hereinafter, “BioMarin”) and Catalyst Pharmaceuticals, Inc., a Delaware corporation (hereinafter, “Catalyst”), each herein referred to individually as “Party” and collectively as “Parties”.

Catalyst Pharmaceuticals, Inc. – AMENDMENT NO. 1 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATON AGREEMENT (May 10th, 2019)

This Amendment No. 1 to the Development, License and Commercialization Agreement (this “Amendment”) is made and entered into as of March 20, 2019 (the “Amendment Effective Date”) by and between Endo Ventures Limited, an Irish company with an office located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation with an office located at 355 Alhambra Circle, Suite 1250, Coral Gables, FL 33134, USA (“Catalyst”).

Catalyst Pharmaceuticals, Inc. – [***] Text omitted and filed separately with the Securities and Exchange Commission/Confidential Treatment Requested under 17 C.F.R. Section 240.24b-2 (December 26th, 2018)

THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and effective as of December 18, 2018 (the “Effective Date”) by and between Endo Ventures Limited, an Irish company, with offices located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation, with offices located at 355 Alhambra Circle Suite 1250, Coral Gables, FL, USA (“Catalyst”).

Catalyst Pharmaceuticals, Inc. – Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets (December 18th, 2018)

CORAL GABLES, Fla., December 18, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment, milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.

Catalyst Pharmaceuticals, Inc. – FOURTH AMENDMENT TO LEASE (August 17th, 2018)

This Fourth Amendment to Lease (this “Fourth Amendment”) is made and entered into by and between PRII 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company (“Landlord”), as successor-in-interest to 355 Alhambra Plaza, Ltd., a Florida limited partnership (“Original Landlord”) and to CPT 355 Alhambra Circle, LLC, a Delaware limited liability company (“Intermediate Landlord”), and CATALYST PHARMACEUTICALS, INC. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Tenant”), effective as of the date this Fourth Amendment is executed by Landlord, as evidenced on the signature page attached hereto (the “Effective Date”).

Catalyst Pharmaceuticals, Inc. – SETTLEMENT AGREEMENT (August 7th, 2018)

THIS SETTLEMENT AGREEMENT (“Agreement”) is effective as of July 26, 2018 (the “Effective Date”) by and among, (i) Aceras BioMedical LLC, a Delaware limited liability company (“Aceras”), in its capacity as Stockholder Representative for the former stockholders (the “Stockholders”) of Huxley Pharmaceuticals, Inc., a Delaware corporation (“Huxley”), that are a party to the SPA (as such term is defined below), (ii) BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), and (iii) Catalyst Pharmaceuticals, Inc. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Catalyst”). Aceras, BioMarin, and Catalyst may be individually referred to herein as a “Party” and collectively referred to herein as the “Parties”.

Catalyst Pharmaceuticals, Inc. – SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT (May 31st, 2018)

This SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 25th day of May, 2018, by and between CATALYST PHARMACEUTICALS, INC., a Delaware corporation (“Company”) and PATRICK J. MCENANY (“Employee”).

Catalyst Pharmaceuticals, Inc. – 14,285,715 Shares Catalyst Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (November 28th, 2017)
Catalyst Pharmaceuticals, Inc. – Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities — FDA grants Special Protocol Assessment agreement for Phase 3 MuSK-MG trial — — Enrollment for second Phase 3 trial for LEMS nearing completion — — Expected NDA submission for Firdapse moves from end of 2017 to first quarter 2018 — (August 30th, 2017)

CORAL GABLES, Fla., August 30, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today provided an update on the status of its Firdapse® (amifampridine phosphate) development activities.

Catalyst Pharmaceuticals, Inc. – CATALYST PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of Debt Securities (July 12th, 2017)

Indenture, dated as of                 , among Catalyst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Catalyst Pharmaceuticals, Inc. – AMENDMENT NO. 1 TO RIGHTS AGREEMENT (September 20th, 2016)

This AMENDMENT NO. 1 TO RIGHTS AGREEMENT, dated as of September 19, 2016 (the “Amendment”), amends that certain Rights Agreement, dated as of September 20, 2011 (the “Rights Agreement”), between Catalyst Pharmaceuticals, Inc. (f/k/a Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the “Company”) and Continental Stock Transfer and Trust Company (the “Rights Agent”). Capitalized terms used, but not otherwise defined, herein shall have the respective meanings ascribed to such terms in the Rights Agreement.

Catalyst Pharmaceuticals, Inc. – FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (June 24th, 2016)

THIS FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 23rd day of June, 2016, by and between CATALYST PHARMACEUTICALS, INC. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Company”), and PATRICK J. MCENANY (“Employee”).

Catalyst Pharmaceuticals, Inc. – Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome Reorganized operations plan projects that current capital resources are adequate to reach NDA acceptance (June 13th, 2016)

CORAL GABLES, Fla., June 13, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a confirmatory Phase 3 study protocol for Firdapse® (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). As part of the clinical protocol for the confirmatory study, Catalyst expects to initiate a small, single-center study with Firdapse during the second half of 2016. Catalyst also expects to announce additional information about the study design and timelines for the study once they are finalized.

Catalyst Pharmaceuticals, Inc. – Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for the Method of Treating Tourette’s Disorder with GABA- Aminotransferase Inactivators Patent Claims Treatment of Tourette’s Disorder with the Entire Class of GABA-AT Inactivators, including CPP-115 and Vigabatrin (October 13th, 2015)

CORAL GABLES, FL, October 13, 2015 – Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/340,749. The patent claims a method of treating Tourette’s Disorder using the entire class of GABA-aminotransferase inactivators, including CPP-115 and vigabatrin (marketed in the U.S. by Lundbeck as Sabril®).

Catalyst Pharmaceuticals, Inc. – CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 THIRD AMENDMENT TO LEASE (August 7th, 2015)

THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the 16th day of March, 2015 (the “Effective Date”), by and between CPT 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company, successor in interest to 355 Alhambra Plaza, Ltd. (“Landlord”), and CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Tenant”).

Catalyst Pharmaceuticals, Inc. – CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF CATALYST PHARMACEUTICAL PARTNERS, INC. a Delaware Corporation (May 22nd, 2015)

Pursuant to the Delaware General Corporation Law (the “DGCL”), the Certificate of Incorporation of CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation, hereinafter referred to as the “Corporation,” is amended as follows:

Catalyst Pharmaceutical Partners, Inc. – CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 THIRD AMENDMENT TO LEASE (March 27th, 2015)

THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the 16th day of March, 2015 (the “Effective Date”), by and between CPT 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company, successor in interest to 355 Alhambra Plaza, Ltd. (“Landlord”), and CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Tenant”).

Catalyst Pharmaceutical Partners, Inc. – 10,000,000 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (February 4th, 2015)
Catalyst Pharmaceutical Partners, Inc. – Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients with CPP-115 (November 24th, 2014)

This patent covers CPP-115 for neurological and psychological uses until 2032, and perhaps longer with extensions allowed under the Patent Term Restoration Act. This patent is also pending in the EU. Catalyst remains optimistic that the pending EU patent will also issue with similar claims in order to confer similar protection and ultimately exclusivity in the EU.

Catalyst Pharmaceutical Partners, Inc. – CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 AMENDMENT NO. 1 TO LICENSE AGREEMENT (April 17th, 2014)

This AMENDMENT NO. 1 TO LICENSE AGREEMENT (herein referred to as “Amendment No. 1”) is made and entered effective as of the 8th day of April, 2014 (the “Effective Date”), by and between BioMarin Pharmaceutical Inc., a Delaware corporation (hereinafter, “BioMarin”) and Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (hereinafter, “Catalyst”), each herein referred to individually as “Party” and collectively as “Parties”.

Catalyst Pharmaceutical Partners, Inc. – 13,023,750 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (April 3rd, 2014)
Catalyst Pharmaceutical Partners, Inc. – CATALYST PHARMACEUTICAL PARTNERS, INC. 2014 STOCK INCENTIVE PLAN (March 4th, 2014)
Catalyst Pharmaceutical Partners, Inc. – SECOND AMENDMENT TO LEASE (February 20th, 2014)

THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the 4th day of February, 2014, by and between CPT 355 ALHAMBRA CIRCLE, LLC, a Delaware limited liability company (“Landlord”), and CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Tenant”).

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE (November 18th, 2013)

CORAL GABLES, Fla., Nov. 18, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that the journal Epilepsia has accepted for publication an original research paper that demonstrates proof of concept of CPP-115 suppressing infantile spasms (IS) in a pre-clinical study. CPP-115 is Catalyst’s next-generation GABA aminotransferase inhibitor being developed for the treatment of IS. Catalyst also announced plans to initiate a Phase I multiple-dose ascending study in the first half of 2014 to evaluate the safety and tolerability of multiple ascending oral doses of CPP-115.

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE (November 14th, 2013)

CORAL GABLES, FL, November 14, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced financial results for the third quarter and nine months period ended September 30, 2013.

Catalyst Pharmaceutical Partners, Inc. – TERMINATION AGREEMENT (November 13th, 2013)

This Termination Agreement (the “Agreement”), is made and entered into as of the latest date of signature below and is effective as of October 1, 2013 (the “Effective Date”) by and between Brookhaven Science Associates, LLC (“Brookhaven”) and Catalyst Pharmaceutical Partners, Inc. (“Catalyst”).

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE (October 29th, 2013)

CORAL GABLES, FL, October 29, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, provided an update on the status of its development activities for its lead product candidate, Firdapse™, which is being evaluated in a pivotal Phase 3 clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE For Further Information Contact: Patrick J. McEnany Melody Carey Catalyst Pharmaceutical Partners Rx Communications Group Chief Executive Officer Co-President (October 15th, 2013)

CORAL GABLES, FL, October 15, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company’s ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the Company continue the trial as planned based on the committee’s review of safety and clinical data from the trial.

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE For Further Information Contact: Patrick McEnany Melody Carey Catalyst Pharmaceutical Partners Rx Communications Group Chief Executive Officer Co-President (September 10th, 2013)

CORAL GABLES, FL, September 10, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported that it has closed its previously announced offering of 8.8 million shares of its common stock in a registered direct public offering. The offering price was $1.72 per share, resulting in gross proceeds of approximately $15.1 million. Roth Capital Partners acted as the exclusive placement agent for the offering and Aegis Capital Corp., Maxim Group LLC and H.C. Wainwright & Co. acted as financial advisers with respect to the offering.

Catalyst Pharmaceutical Partners, Inc. – CATALYST PHARMACEUTICAL PARTNERS, INC. 8,800,000 shares of Common Stock PLACEMENT AGENT AGREEMENT (September 5th, 2013)
Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE For Further Information Contact: Patrick J. McEnany Melody Carey Catalyst Pharmaceutical Partners Rx Communications Group Chief Executive Officer Co-President (September 5th, 2013)

CORAL GABLES, FL, September 5, 2013 – Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) announced today that it has entered into definitive agreements to sell 8.8 million shares of its common stock in a registered direct public offering. The offering price for each share of common stock is $1.72, resulting in gross proceeds of approximately $15.1 million.

Catalyst Pharmaceutical Partners, Inc. – Catalyst Pharmaceutical Partners, Inc. (September 5th, 2013)
Catalyst Pharmaceutical Partners, Inc. – FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (August 29th, 2013)

THIS FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of this 28th day of August, 2013, by and between CATALYST PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“Company”), and PATRICK J. MCENANY (“Employee”).

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE For Further Information Contact: Patrick J. McEnany Melody Carey Catalyst Pharmaceutical Partners Rx Communications Group Chief Executive Officer Co-President (August 27th, 2013)

CORAL GABLES, FL, August 27, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that its investigational product Firdapse™ (amifampridine phosphate) has received “Breakthrough Therapy Designation” by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse™ is Catalyst’s investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.

Catalyst Pharmaceutical Partners, Inc. – NEWS RELEASE FOR IMMEDIATE RELEASE For Further Information Contact: Patrick J. McEnany Melody Carey Catalyst Pharmaceutical Partners Rx Communications Group Chief Executive Officer Co-President (August 15th, 2013)

CORAL GABLES, FL, August 15, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced financial results for the second quarter and six months period ended June 30, 2013.